Weiwen Ying is an avid drug hunter with more than 15 years of research and development experience. While his tenure at Synta Pharmaceuticals, he created and championed the Hsp90 inhibitor program, that led to the clinical candidate ganetespib which completed the Ph3 trials. He was also the co-creator of the Hsp90 inhibitor drug conjugate (HDC) program.
Dinesh Chimmanamada is an innovative concept and drug creator, specifically in oncology space. During his more than a decade long research at Synta pharmaceuticals, he has worked on multiple oncology programs. He co-created the Hsp90 Inhibitor Drug Conjugate (HDC) program, which led to the generation of a clinical candidate STA-8666.